{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:52:00Z","timestamp":1782604320143,"version":"3.54.5"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T00:00:00Z","timestamp":1692057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T00:00:00Z","timestamp":1692057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s10067-023-06731-4","type":"journal-article","created":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T14:02:43Z","timestamp":1692108163000},"page":"579-589","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Does baricitinib reduce disease activity in patients with systemic lupus erythematosus? A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7787-5508","authenticated-orcid":false,"given":"Basma Ehab","family":"Amer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6667-0021","authenticated-orcid":false,"given":"Eslam","family":"Afifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5721-8110","authenticated-orcid":false,"given":"Adel","family":"Mouffokes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3849-0995","authenticated-orcid":false,"given":"Abdullah Ashraf","family":"Hamad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7065-381X","authenticated-orcid":false,"given":"Ahmed Mostafa","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8266-0245","authenticated-orcid":false,"given":"Omar Ahmed","family":"Abdelwahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,15]]},"reference":[{"key":"6731_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2016.39","volume":"2","author":"A Kaul","year":"2016","unstructured":"Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, Van Vollenhoven R, Ruiz-Irastorza G, Hughes G (2016) Systemic lupus erythematosus. Nat Rev Dis Prim 2:1\u201322. https:\/\/doi.org\/10.1038\/nrdp.2016.39","journal-title":"Nat Rev Dis Prim"},{"key":"6731_CR2","doi-asserted-by":"publisher","first-page":"313","DOI":"10.7326\/aitc202006020","volume":"18","author":"AP Rao","year":"2016","unstructured":"Rao AP, Raghuram J (2016) Systemic lupus erythematosus. Indian J Pract Pediatr 18:313\u2013319. https:\/\/doi.org\/10.7326\/aitc202006020","journal-title":"Indian J Pract Pediatr"},{"key":"6731_CR3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1100359","author":"G Tsokos","year":"2011","unstructured":"Tsokos G (2011) Systemic lupus erythematosus. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMra1100359","journal-title":"N Engl J Med"},{"key":"6731_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms20246231","volume":"20","author":"DYH Yap","year":"2019","unstructured":"Yap DYH, Chan TM (2019) B cell abnormalities in systemic lupus erythematosus and lupus nephritis\u2014role in pathogenesis and effect of immunosuppressive treatments. Int J Mol Sci 20:1\u201318. https:\/\/doi.org\/10.3390\/ijms20246231","journal-title":"Int J Mol Sci"},{"key":"6731_CR5","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(13)60954-X","volume":"382","author":"M Wahren-Herlenius","year":"2013","unstructured":"Wahren-Herlenius M, D\u00f6rner T (2013) Immunopathogenic mechanisms of systemic autoimmune disease. Lancet 382:819\u2013831. https:\/\/doi.org\/10.1016\/S0140-6736(13)60954-X","journal-title":"Lancet"},{"issue":"1","key":"6731_CR6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41572-019-0141-9","volume":"6","author":"HJ Anders","year":"2020","unstructured":"Anders HJ, Saxena R, Zhao M, hui, Parodis I, Salmon JE, Mohan C (2020) Lupus nephritis. Nat Rev Dis Primers 6(1):7. https:\/\/doi.org\/10.1038\/s41572-019-0141-9","journal-title":"Nat Rev Dis Primers"},{"key":"6731_CR7","doi-asserted-by":"publisher","first-page":"675","DOI":"10.4049\/jimmunol.1800300","volume":"202","author":"RG Bonegio","year":"2019","unstructured":"Bonegio RG, Lin JD, Beaudette-Zlatanova B, York MR, Menn-Josephy H, Yasuda K (2019) Lupus-associated immune complexes activate human neutrophils in an Fc\u03b3RIIA-dependent but TLR-independent response. J Immunol 202:675\u2013683. https:\/\/doi.org\/10.4049\/jimmunol.1800300","journal-title":"J Immunol"},{"key":"6731_CR8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/13543784.2019.1551358","volume":"28","author":"CC Mok","year":"2019","unstructured":"Mok CC (2019) The Jakinibs in systemic lupus erythematosus: progress and prospects. Expert Opin Investig Drugs 28:85\u201392. https:\/\/doi.org\/10.1080\/13543784.2019.1551358","journal-title":"Expert Opin Investig Drugs"},{"key":"6731_CR9","doi-asserted-by":"publisher","unstructured":"R\u00f6nnblom L, Alm GV (2001) A pivotal role for the natural interferon \u03b1-producing cells (plasmacytoid dendritic cells) in the\u00a0pathogenesis of lupus. J Exp Med 17;194(12):F59\u201363. https:\/\/doi.org\/10.1084\/jem.194.12.f59","DOI":"10.1084\/jem.194.12.f59"},{"key":"6731_CR10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1177\/1535370218824547","volume":"244","author":"M Larosa","year":"2019","unstructured":"Larosa M, Zen M, Gatto M, Jesus D, Zanatta E, Iaccarino L, In\u00eas L, Doria A (2019) IL-12 and IL-23\/Th17 axis in systemic lupus erythematosus. Exp Biol Med 244:42\u201351. https:\/\/doi.org\/10.1177\/1535370218824547","journal-title":"Exp Biol Med"},{"issue":"6485","key":"6731_CR11","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/370151a0","volume":"370","author":"J Johnston","year":"1994","unstructured":"Johnston J, Kawamura M, Kirken R, Chen Y, Blake T, Shibuya T, Ortaldo J, McVicar DOJ (1994) Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2. Nature 370(6485):151\u2013153. https:\/\/doi.org\/10.1038\/370151a0","journal-title":"Nature"},{"key":"6731_CR12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/377065a0","volume":"377","author":"P Macchi","year":"1995","unstructured":"Macchi P, Villa A, Giliani S, Sacco MG, Frattini A, Porta F, Ugazio AG, Johnston JA, Candotti F, O\u2019sheai JJ, Vezzoni P, Notarangelo LD (1995) Mutations of jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 377:65\u201368","journal-title":"Nature"},{"key":"6731_CR13","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nrd.2017.201","volume":"16","author":"DM Schwartz","year":"2017","unstructured":"Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O\u2019Shea JJ (2017) JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov 16:843\u2013862. https:\/\/doi.org\/10.1038\/nrd.2017.201","journal-title":"Nat Rev Drug Discov"},{"key":"6731_CR14","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/ni.3691","volume":"18","author":"AV Villarino","year":"2017","unstructured":"Villarino AV, Kanno Y, O\u2019Shea JJ (2017) Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat Immunol 18:374\u2013384. https:\/\/doi.org\/10.1038\/ni.3691","journal-title":"Nat Immunol"},{"key":"6731_CR15","doi-asserted-by":"publisher","first-page":"5298","DOI":"10.4049\/jimmunol.0902819","volume":"184","author":"JS Fridman","year":"2010","unstructured":"Fridman JS, Scherle PA, Collins R, Burn TC, Li Y, Li J, Covington MB, Thomas B, Collier P, Favata MF, Wen X, Shi J, McGee R, Haley PJ, Shepard S, Rodgers JD, Yeleswaram S, Hollis G, Newton RC, Metcalf B, Friedman SM, Vaddi K (2010) Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol 184:5298\u20135307. https:\/\/doi.org\/10.4049\/jimmunol.0902819","journal-title":"J Immunol"},{"key":"6731_CR16","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s40265-017-0723-3","volume":"77","author":"A Markham","year":"2017","unstructured":"Markham A (2017) Baricitinib: first global approval. Drugs 77:697\u2013704. https:\/\/doi.org\/10.1007\/s40265-017-0723-3","journal-title":"Drugs"},{"key":"6731_CR17","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","volume":"392","author":"DJ Wallace","year":"2018","unstructured":"Wallace DJ, Furie RA, Tanaka Y, Kalunian KC, Mosca M, Petri MA, D\u00f6rner T, Cardiel MH, Bruce IN, Gomez E, Carmack T, DeLozier AM, Janes JM, Linnik MD, de Bono S, Silk ME, Hoffman RW (2018) Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 392:222\u2013231. https:\/\/doi.org\/10.1016\/S0140-6736(18)31363-1","journal-title":"Lancet"},{"key":"6731_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/lupus-2020-000424","volume":"7","author":"T D\u00f6rner","year":"2020","unstructured":"D\u00f6rner T, Tanaka Y, Petri MA, Smolen JS, Wallace DJ, Dow ER, Higgs RE, Rocha G, Crowe B, Benschop RJ, Byers NL, Silk ME, De Bono S, Fantini D, Hoffman RW (2020) Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways. Lupus Sci Med 7:1\u201310. https:\/\/doi.org\/10.1136\/lupus-2020-000424","journal-title":"Lupus Sci Med"},{"key":"6731_CR19","doi-asserted-by":"publisher","first-page":"i43","DOI":"10.1093\/rheumatology\/key276","volume":"58","author":"GE Fragoulis","year":"2019","unstructured":"Fragoulis GE, Mcinnes IB, Siebert S (2019) JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatol (United Kingdom) 58:i43\u2013i54. https:\/\/doi.org\/10.1093\/rheumatology\/key276","journal-title":"Rheumatol (United Kingdom)"},{"key":"6731_CR20","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/s0140-6736(22)02546-6","volume":"401","author":"M Petri","year":"2023","unstructured":"Petri M, Bruce IN, D\u00f6rner T, Tanaka Y, Morand EF, Kalunian KC, Cardiel MH, Silk ME, Dickson CL, Meszaros G, Zhang L, Jia B, Zhao Y, McVeigh CJ, Mosca M (2023) Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II). Lancet 401:1011\u20131019. https:\/\/doi.org\/10.1016\/s0140-6736(22)02546-6","journal-title":"Lancet"},{"issue":"10381","key":"6731_CR21","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/s0140-6736(22)02607-1","volume":"401","author":"EF Morand","year":"2023","unstructured":"Morand EF, Vital EM, Petri M, van Vollenhoven R, Wallace DJ, Mosca M, Furie RA, Silk ME, Dickson CL, Meszaros G, Jia B, Crowe B, de la Torre I, D\u00f6rner T (2023) Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebocontrolled, phase 3 trial (SLE-BRAVE-I). Lancet 401(10381):1001\u20131010. https:\/\/doi.org\/10.1016\/s0140-6736(22)02607-1","journal-title":"Lancet"},{"key":"6731_CR22","doi-asserted-by":"publisher","unstructured":"Page MJ, Mckenzie JE, Bossuyt PM, Boutron I, Hoffmann C, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-wilson E, Mcdonald S, Mcguinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement\u202f: an updated guideline for reporting systematic reviews Systematic reviews and Meta-Analyses.\u00a0BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"key":"6731_CR23","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJWV (2022) Cochrane handbook for systematic reviews of interventions version 6.3 (updated February 2022). Cochrane.\u00a0Available from www.training.cochrane.org\/handbook"},{"key":"6731_CR24","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1002\/art.1780400928","volume":"40","author":"MC Hochberg","year":"1997","unstructured":"Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1997","journal-title":"Arthritis Rheum"},{"key":"6731_CR25","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1002\/art.24698","volume":"61","author":"RA Furie","year":"2009","unstructured":"Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, Chatham WW, Strand V, Weinstein A, Chevrier MR, Zhong ZJ, Freimuth WW (2009) Novel evidence-based systemic lupus erythematosus responder index. Arthritis Care Res 61:1143\u20131151. https:\/\/doi.org\/10.1002\/art.24698","journal-title":"Arthritis Care Res"},{"key":"6731_CR26","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3899\/jrheum.130030","volume":"40","author":"Z Touma","year":"2013","unstructured":"Touma Z, Urowitz MB, Gladman DD (2013) Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 Website. J Rheumatol 40:733. https:\/\/doi.org\/10.3899\/jrheum.130030","journal-title":"J Rheumatol"},{"key":"6731_CR27","doi-asserted-by":"publisher","first-page":"4113","DOI":"10.1002\/art.23130","volume":"56","author":"CS Yee","year":"2007","unstructured":"Yee CS, Farewell V, Isenberg DA, Rahman A, Teh LS, Griffiths B, Bruce IN, Ahmad Y, Prabu A, Akil M, McHugh N, D\u2019Cruz D, Khamashta MA, Maddison P, Gordon C (2007) British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 56:4113\u20134119. https:\/\/doi.org\/10.1002\/art.23130","journal-title":"Arthritis Rheum"},{"key":"6731_CR28","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1191\/096120399680411281","volume":"8","author":"M Petri","year":"1999","unstructured":"Petri M, Buyon JKM (1999) Classification and definition of major flares in SLE clinical trials. Lupus 8:685\u2013691. https:\/\/doi.org\/10.1191\/096120399680411281","journal-title":"Lupus"},{"key":"6731_CR29","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1093\/rheumatology\/kex368","volume":"57","author":"K Kalunian","year":"2018","unstructured":"Kalunian K, Urowitz M, Isenberg D, Merrill J, Petri M, Furie R, Morgan-Cox M, Taha R, Watts S, Silk MLM (2018) Running head: SLE Responder Index title: Clinical trial parameters that influence outcomes in lupus trials that use the Systemic Lupus Erythematosus Responder Index endpoint. Rheumatol 57:125\u2013133. https:\/\/doi.org\/10.1093\/rheumatology\/kex368","journal-title":"Rheumatol"},{"key":"6731_CR30","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","volume":"75","author":"K Franklyn","year":"2016","unstructured":"Franklyn K, Lau CS, Navarra SV, Louthrenoo W, Lateef A, Hamijoyo L, Wahono CS, Le CS, Jin O, Morton S, Hoi A, Huq M, Nikpour M, Morand EF (2016) Definition and initial validation of a lupus low disease activity state (LLDAS). Ann Rheum Dis 75:1615\u20131621. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207726","journal-title":"Ann Rheum Dis"},{"key":"6731_CR31","doi-asserted-by":"publisher","first-page":"AB6","DOI":"10.1016\/j.jaad.2005.01.045","volume":"52","author":"J Albrecht","year":"2005","unstructured":"Albrecht J, Taylor \u00c3L, Berlin JA, Dulay S, Ang \u00c3G, Fakharzadeh S, Kantor J, Kim \u00c3E, Militello \u00c3G, Mcginnis \u00c3K, Richardson \u00c3S, Treat \u00c3J, Vittorio C, Van Voorhees \u00c3A, VPW \u00c3, Al AET (2005) The CLASI (Cutaneous LE Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Am Acad Dermatol 52:AB6. https:\/\/doi.org\/10.1016\/j.jaad.2005.01.045","journal-title":"J Am Acad Dermatol"},{"key":"6731_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan-a web and mobile app for systematic reviews. Syst Rev 5:1\u201310. https:\/\/doi.org\/10.1186\/s13643-016-0384-4","journal-title":"Syst Rev"},{"key":"6731_CR33","doi-asserted-by":"publisher","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials.\u00a0BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","DOI":"10.1136\/bmj.l4898"},{"key":"6731_CR34","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. Br Med J 315:629\u2013634. https:\/\/doi.org\/10.1136\/bmj.315.7109.629","journal-title":"Br Med J"},{"key":"#cr-split#-6731_CR35.1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 - . Identifier NCT03843125, A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)"},{"key":"#cr-split#-6731_CR35.2","unstructured":"2019 Sep 9 [cited 2023 May 23]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03843125"},{"key":"#cr-split#-6731_CR36.1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 - . Identifier NCT05432531, Efficiency of Use of Baracetinib in Treatment of Lupus Nephritis"},{"key":"#cr-split#-6731_CR36.2","unstructured":"2022 June 27 [cited 2023 May 23]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05432531"},{"key":"6731_CR37","first-page":"2002","volume":"9","author":"A Lorenzo-Vizcaya","year":"2011","unstructured":"Lorenzo-Vizcaya A, Isenberg DA (2011) Clinical trials in systemic lupus erythematosus\u2013the dilemma. why phase III trials failed to confirm the promising results of phase II trials? Ann Rheum Dis 9:2002","journal-title":"Ann Rheum Dis"},{"key":"6731_CR38","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1080\/1744666X.2019.1608821","volume":"15","author":"S Kubo","year":"2019","unstructured":"Kubo S, Nakayamada S, Tanaka Y (2019) Baricitinib for the treatment of rheumatoid arthritis and systemic lupus erythematosus: a 2019 update. Expert Rev Clin Immunol 15:693\u2013700. https:\/\/doi.org\/10.1080\/1744666X.2019.1608821","journal-title":"Expert Rev Clin Immunol"},{"key":"6731_CR39","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.2147\/JIR.S397639","volume":"16","author":"R Huo","year":"2023","unstructured":"Huo R, Huang X, Yang Y, Lin J (2023) Potential use of Janus kinase inhibitors in the treatment of systemic lupus erythematosus. J Inflamm Res 16:1471\u20131478. https:\/\/doi.org\/10.2147\/JIR.S397639","journal-title":"J Inflamm Res"},{"key":"6731_CR40","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","volume":"18","author":"Y Tanaka","year":"2022","unstructured":"Tanaka Y, Luo Y, O\u2019Shea JJ, Nakayamada S (2022) Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol 18:133\u2013145. https:\/\/doi.org\/10.1038\/s41584-021-00726-8","journal-title":"Nat Rev Rheumatol"},{"key":"6731_CR41","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.1002\/art.24803","volume":"60","author":"JW Bauer","year":"2009","unstructured":"Bauer JW, Petri M, Batliwalla FM, Koeuth T, Wilson J, Slattery C, Panoskaltsis-Mortari A, Gregersen PK, Behrens TW, Baechler EC (2009) Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum 60:3098\u20133107. https:\/\/doi.org\/10.1002\/art.24803","journal-title":"Arthritis Rheum"},{"key":"6731_CR42","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1136\/annrheumdis-2022-222335","volume":"81","author":"T D\u00f6rner","year":"2022","unstructured":"D\u00f6rner T, Tanaka Y, Dow ER, Koch AE, Silk M, Ross Terres JA, Sims JT, Sun Z, De La Torre I, Petri M (2022) Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus. Ann Rheum Dis 81:1267\u20131272. https:\/\/doi.org\/10.1136\/annrheumdis-2022-222335","journal-title":"Ann Rheum Dis"},{"key":"6731_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2021.704526","volume":"12","author":"J Lee","year":"2021","unstructured":"Lee J, Park Y, Jang SG, Hong SM, Song YS, Kim MJ, Baek SY, Park SH, Kwok SK (2021) Baricitinib attenuates autoimmune phenotype and podocyte injury in a murine model of systemic lupus erythematosus. Front Immunol 12:1\u201311. https:\/\/doi.org\/10.3389\/fimmu.2021.704526","journal-title":"Front Immunol"},{"key":"6731_CR44","doi-asserted-by":"publisher","first-page":"4910","DOI":"10.1007\/s12325-022-02281-4","volume":"39","author":"T Bieber","year":"2022","unstructured":"Bieber T, Feist E, Irvine AD, Harigai M, Haladyj E, Ball S, Deberdt W, Issa M, Grond S, Taylor PC (2022) A review of safety outcomes from clinical trials of baricitinib in rheumatology, dermatology and COVID-19. Adv Ther 39:4910\u20134960. https:\/\/doi.org\/10.1007\/s12325-022-02281-4","journal-title":"Adv Ther"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06731-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-023-06731-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06731-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T11:11:09Z","timestamp":1706785869000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-023-06731-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,15]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["6731"],"URL":"https:\/\/doi.org\/10.1007\/s10067-023-06731-4","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,15]]},"assertion":[{"value":"1 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}